fda import alert green list glp-1 semaglutide tirzepatide 2025 introduces "Green List" for drug ingredients | Bob Durkin posted on the topic Indications for GLP-1/GIP RA Summary

Oral/intraperitoneal glucose tolerance test and insulin tolerance test were performed

It is not known whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans

It also improves the bodys ability to handle fat, resulting in better cholesterol and triglyceride levels

The evidence for microdosing as a maintenance strategy is still emerging

Verbal representations or general marketing language may not reflect actual policy terms controlling refund decisions

Current clinical evidence suggests GLP-1 medications should be discontinued before conception and throughout pregnancy, though individual circumstances vary based on metabolic health and medical history